Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19
- Autores
- Silva, Mauro Gastón; Corradi, Gerardo Raul; Pérez Duhalde, Juan I.; Nuñez, Myriam; Cela, Eliana Maiten; Gonzales Maglio, Daniel H.; Brizzio, Ana; Salazar, Martin Rogelio Enrique; Espeche, Walter; Gironacci, Mariela Mercedes
- Año de publicación
- 2022
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Background: Besides its counterbalancing role of the renin-angiotensin system (RAS), angiotensin-converting enzyme (ACE) 2 is the receptor for the type 2 coronavirus that causes severe acute respiratory syndrome, the etiological agent of COVID-19. COVID-19 is associated with increased plasmatic ACE2 levels, although conflicting results have been reported regarding angiotensin (Ang) II and Ang-(1−7) levels. We investigated plasmatic ACE2 protein levels and enzymatic activity and Ang II and Ang-(1−7) levels in normotensive and hypertensive patients hospitalized with COVID-19 compared to healthy subjects. Methods: Ang II and Ang-(1−7), and ACE2 activity and protein levels were measured in 93 adults (58 % (n = 54) normotensive and 42 % (n = 39) hypertensive) hospitalized with COVID-19. Healthy, normotensive (n = 33) and hypertensive (n = 7) outpatient adults comprised the control group. Results: COVID-19 patients displayed higher ACE2 enzymatic activity and protein levels than healthy subjects. Within the COVID-19 group, ACE2 activity and protein levels were not different between normotensive and hypertensive-treated patients, not even between COVID-19 hypertensive patients under RAS blockade treatment and those treated with other antihypertensive medications. Ang II and Ang-(1−7) levels significantly decreased in COVID-19 patients. When COVID-19 patients under RAS blockade treatment were excluded from the analysis, ACE2 activity and protein levels remained higher and Ang II and Ang-(1−7) levels lower in COVID-19 patients compared to healthy people. Conclusions: Our results support the involvement of RAS in COVID-19, even when patients under RAS blockade treatment were excluded. The increased circulating ACE2 suggest higher ACE2 expression and shedding.
Fil: Silva, Mauro Gastón. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Química Biológica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Química y Físico-Química Biológicas "Prof. Alejandro C. Paladini". Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Química y Físico-Química Biológicas; Argentina
Fil: Corradi, Gerardo Raul. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Química y Físico-Química Biológicas "Prof. Alejandro C. Paladini". Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Química y Físico-Química Biológicas; Argentina
Fil: Pérez Duhalde, Juan I.. Hospital San Martín, la Plata; Argentina
Fil: Nuñez, Myriam. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Físico Matemática. Cátedra de Matemáticas; Argentina
Fil: Cela, Eliana Maiten. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
Fil: Gonzales Maglio, Daniel H.. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina
Fil: Brizzio, Ana. Hospital San Martín de La Plata; Argentina
Fil: Salazar, Martin Rogelio Enrique. Hospital San Martín de La Plata; Argentina
Fil: Espeche, Walter. Hospital San Martín de La Plata; Argentina
Fil: Gironacci, Mariela Mercedes. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina - Materia
-
ANGIOTENSIN
ANGIOTENSIN RECEPTOR BLOCKERS
ANGIOTENSIN-CONVERTING ENZYME 2
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
COVID-19
HYPERTENSION - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/163119
Ver los metadatos del registro completo
id |
CONICETDig_fc381b3f93f85c95f75d1cf86abc0032 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/163119 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19Silva, Mauro GastónCorradi, Gerardo RaulPérez Duhalde, Juan I.Nuñez, MyriamCela, Eliana MaitenGonzales Maglio, Daniel H.Brizzio, AnaSalazar, Martin Rogelio EnriqueEspeche, WalterGironacci, Mariela MercedesANGIOTENSINANGIOTENSIN RECEPTOR BLOCKERSANGIOTENSIN-CONVERTING ENZYME 2ANGIOTENSIN-CONVERTING ENZYME INHIBITORSCOVID-19HYPERTENSIONhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Background: Besides its counterbalancing role of the renin-angiotensin system (RAS), angiotensin-converting enzyme (ACE) 2 is the receptor for the type 2 coronavirus that causes severe acute respiratory syndrome, the etiological agent of COVID-19. COVID-19 is associated with increased plasmatic ACE2 levels, although conflicting results have been reported regarding angiotensin (Ang) II and Ang-(1−7) levels. We investigated plasmatic ACE2 protein levels and enzymatic activity and Ang II and Ang-(1−7) levels in normotensive and hypertensive patients hospitalized with COVID-19 compared to healthy subjects. Methods: Ang II and Ang-(1−7), and ACE2 activity and protein levels were measured in 93 adults (58 % (n = 54) normotensive and 42 % (n = 39) hypertensive) hospitalized with COVID-19. Healthy, normotensive (n = 33) and hypertensive (n = 7) outpatient adults comprised the control group. Results: COVID-19 patients displayed higher ACE2 enzymatic activity and protein levels than healthy subjects. Within the COVID-19 group, ACE2 activity and protein levels were not different between normotensive and hypertensive-treated patients, not even between COVID-19 hypertensive patients under RAS blockade treatment and those treated with other antihypertensive medications. Ang II and Ang-(1−7) levels significantly decreased in COVID-19 patients. When COVID-19 patients under RAS blockade treatment were excluded from the analysis, ACE2 activity and protein levels remained higher and Ang II and Ang-(1−7) levels lower in COVID-19 patients compared to healthy people. Conclusions: Our results support the involvement of RAS in COVID-19, even when patients under RAS blockade treatment were excluded. The increased circulating ACE2 suggest higher ACE2 expression and shedding.Fil: Silva, Mauro Gastón. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Química Biológica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Química y Físico-Química Biológicas "Prof. Alejandro C. Paladini". Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Química y Físico-Química Biológicas; ArgentinaFil: Corradi, Gerardo Raul. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Química y Físico-Química Biológicas "Prof. Alejandro C. Paladini". Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Química y Físico-Química Biológicas; ArgentinaFil: Pérez Duhalde, Juan I.. Hospital San Martín, la Plata; ArgentinaFil: Nuñez, Myriam. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Físico Matemática. Cátedra de Matemáticas; ArgentinaFil: Cela, Eliana Maiten. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; ArgentinaFil: Gonzales Maglio, Daniel H.. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; ArgentinaFil: Brizzio, Ana. Hospital San Martín de La Plata; ArgentinaFil: Salazar, Martin Rogelio Enrique. Hospital San Martín de La Plata; ArgentinaFil: Espeche, Walter. Hospital San Martín de La Plata; ArgentinaFil: Gironacci, Mariela Mercedes. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; ArgentinaElsevier France-Editions Scientifiques Medicales Elsevier2022-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/163119Silva, Mauro Gastón; Corradi, Gerardo Raul; Pérez Duhalde, Juan I.; Nuñez, Myriam; Cela, Eliana Maiten; et al.; Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19; Elsevier France-Editions Scientifiques Medicales Elsevier; Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie; 152; 3201; 5-2022; 1-80753-3322CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.biopha.2022.113201info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S075333222200590Xinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:47:27Zoai:ri.conicet.gov.ar:11336/163119instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:47:27.318CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19 |
title |
Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19 |
spellingShingle |
Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19 Silva, Mauro Gastón ANGIOTENSIN ANGIOTENSIN RECEPTOR BLOCKERS ANGIOTENSIN-CONVERTING ENZYME 2 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS COVID-19 HYPERTENSION |
title_short |
Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19 |
title_full |
Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19 |
title_fullStr |
Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19 |
title_full_unstemmed |
Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19 |
title_sort |
Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19 |
dc.creator.none.fl_str_mv |
Silva, Mauro Gastón Corradi, Gerardo Raul Pérez Duhalde, Juan I. Nuñez, Myriam Cela, Eliana Maiten Gonzales Maglio, Daniel H. Brizzio, Ana Salazar, Martin Rogelio Enrique Espeche, Walter Gironacci, Mariela Mercedes |
author |
Silva, Mauro Gastón |
author_facet |
Silva, Mauro Gastón Corradi, Gerardo Raul Pérez Duhalde, Juan I. Nuñez, Myriam Cela, Eliana Maiten Gonzales Maglio, Daniel H. Brizzio, Ana Salazar, Martin Rogelio Enrique Espeche, Walter Gironacci, Mariela Mercedes |
author_role |
author |
author2 |
Corradi, Gerardo Raul Pérez Duhalde, Juan I. Nuñez, Myriam Cela, Eliana Maiten Gonzales Maglio, Daniel H. Brizzio, Ana Salazar, Martin Rogelio Enrique Espeche, Walter Gironacci, Mariela Mercedes |
author2_role |
author author author author author author author author author |
dc.subject.none.fl_str_mv |
ANGIOTENSIN ANGIOTENSIN RECEPTOR BLOCKERS ANGIOTENSIN-CONVERTING ENZYME 2 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS COVID-19 HYPERTENSION |
topic |
ANGIOTENSIN ANGIOTENSIN RECEPTOR BLOCKERS ANGIOTENSIN-CONVERTING ENZYME 2 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS COVID-19 HYPERTENSION |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 |
dc.description.none.fl_txt_mv |
Background: Besides its counterbalancing role of the renin-angiotensin system (RAS), angiotensin-converting enzyme (ACE) 2 is the receptor for the type 2 coronavirus that causes severe acute respiratory syndrome, the etiological agent of COVID-19. COVID-19 is associated with increased plasmatic ACE2 levels, although conflicting results have been reported regarding angiotensin (Ang) II and Ang-(1−7) levels. We investigated plasmatic ACE2 protein levels and enzymatic activity and Ang II and Ang-(1−7) levels in normotensive and hypertensive patients hospitalized with COVID-19 compared to healthy subjects. Methods: Ang II and Ang-(1−7), and ACE2 activity and protein levels were measured in 93 adults (58 % (n = 54) normotensive and 42 % (n = 39) hypertensive) hospitalized with COVID-19. Healthy, normotensive (n = 33) and hypertensive (n = 7) outpatient adults comprised the control group. Results: COVID-19 patients displayed higher ACE2 enzymatic activity and protein levels than healthy subjects. Within the COVID-19 group, ACE2 activity and protein levels were not different between normotensive and hypertensive-treated patients, not even between COVID-19 hypertensive patients under RAS blockade treatment and those treated with other antihypertensive medications. Ang II and Ang-(1−7) levels significantly decreased in COVID-19 patients. When COVID-19 patients under RAS blockade treatment were excluded from the analysis, ACE2 activity and protein levels remained higher and Ang II and Ang-(1−7) levels lower in COVID-19 patients compared to healthy people. Conclusions: Our results support the involvement of RAS in COVID-19, even when patients under RAS blockade treatment were excluded. The increased circulating ACE2 suggest higher ACE2 expression and shedding. Fil: Silva, Mauro Gastón. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Química Biológica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Química y Físico-Química Biológicas "Prof. Alejandro C. Paladini". Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Química y Físico-Química Biológicas; Argentina Fil: Corradi, Gerardo Raul. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Química y Físico-Química Biológicas "Prof. Alejandro C. Paladini". Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Química y Físico-Química Biológicas; Argentina Fil: Pérez Duhalde, Juan I.. Hospital San Martín, la Plata; Argentina Fil: Nuñez, Myriam. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Físico Matemática. Cátedra de Matemáticas; Argentina Fil: Cela, Eliana Maiten. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina Fil: Gonzales Maglio, Daniel H.. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina Fil: Brizzio, Ana. Hospital San Martín de La Plata; Argentina Fil: Salazar, Martin Rogelio Enrique. Hospital San Martín de La Plata; Argentina Fil: Espeche, Walter. Hospital San Martín de La Plata; Argentina Fil: Gironacci, Mariela Mercedes. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Estudios de la Inmunidad Humoral Prof. Ricardo A. Margni; Argentina |
description |
Background: Besides its counterbalancing role of the renin-angiotensin system (RAS), angiotensin-converting enzyme (ACE) 2 is the receptor for the type 2 coronavirus that causes severe acute respiratory syndrome, the etiological agent of COVID-19. COVID-19 is associated with increased plasmatic ACE2 levels, although conflicting results have been reported regarding angiotensin (Ang) II and Ang-(1−7) levels. We investigated plasmatic ACE2 protein levels and enzymatic activity and Ang II and Ang-(1−7) levels in normotensive and hypertensive patients hospitalized with COVID-19 compared to healthy subjects. Methods: Ang II and Ang-(1−7), and ACE2 activity and protein levels were measured in 93 adults (58 % (n = 54) normotensive and 42 % (n = 39) hypertensive) hospitalized with COVID-19. Healthy, normotensive (n = 33) and hypertensive (n = 7) outpatient adults comprised the control group. Results: COVID-19 patients displayed higher ACE2 enzymatic activity and protein levels than healthy subjects. Within the COVID-19 group, ACE2 activity and protein levels were not different between normotensive and hypertensive-treated patients, not even between COVID-19 hypertensive patients under RAS blockade treatment and those treated with other antihypertensive medications. Ang II and Ang-(1−7) levels significantly decreased in COVID-19 patients. When COVID-19 patients under RAS blockade treatment were excluded from the analysis, ACE2 activity and protein levels remained higher and Ang II and Ang-(1−7) levels lower in COVID-19 patients compared to healthy people. Conclusions: Our results support the involvement of RAS in COVID-19, even when patients under RAS blockade treatment were excluded. The increased circulating ACE2 suggest higher ACE2 expression and shedding. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-05 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/163119 Silva, Mauro Gastón; Corradi, Gerardo Raul; Pérez Duhalde, Juan I.; Nuñez, Myriam; Cela, Eliana Maiten; et al.; Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19; Elsevier France-Editions Scientifiques Medicales Elsevier; Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie; 152; 3201; 5-2022; 1-8 0753-3322 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/163119 |
identifier_str_mv |
Silva, Mauro Gastón; Corradi, Gerardo Raul; Pérez Duhalde, Juan I.; Nuñez, Myriam; Cela, Eliana Maiten; et al.; Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19; Elsevier France-Editions Scientifiques Medicales Elsevier; Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie; 152; 3201; 5-2022; 1-8 0753-3322 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.biopha.2022.113201 info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S075333222200590X |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier France-Editions Scientifiques Medicales Elsevier |
publisher.none.fl_str_mv |
Elsevier France-Editions Scientifiques Medicales Elsevier |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842268860120563712 |
score |
13.13397 |